Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: a systematic review and meta-analysis

Published:2023-12 Issue:6 Volume:8 Page:102198
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Rizzo A.,Schipilliti F.M.,Di Costanzo F.,Acquafredda S.,Arpino G.,Puglisi F.,Del Mastro L.,Montemurro F.,De Laurentiis M.,Giuliano M.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference31 articles.

1. Breast cancer: presentation, investigation and management;Katsura;Br J Hosp Med (Lond),2022

2. Triple-negative breast cancer molecular subtyping and treatment progress;Yin;Breast Cancer Res,2020

3. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment;Garrido-Castro;Cancer Discov,2019

4. Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis;Xin;BMC Cancer,2021

5. Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival;Sobral-Leite;Oncoimmunology,2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Iron-chelated and GSH-responsive polymersome nanoreactors facilitating therapeutic cascade reactions in cooperative starvation-ferroptosis therapy;Journal of Drug Delivery Science and Technology;2024-09

2. Impact of neoadjuvant chemotherapy on perioperative immune function in breast cancer patients: a propensity score-matched retrospective study;Scientific Reports;2024-08-13